A Study for Type 2 Diabetic Patients

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to compare the insulin lispro low mixture (1, 2 or 3 daily injections) with insulin glargine (alone or with 1, 2 or 3 insulin lispro daily injections) on lowering the blood sugar level

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Insulin; Insulin Glargine; Insulin Lispro; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus

• Receiving oral antihyperglycemic medications (including metformin) without insulin injection in the last 90 days

• Hemoglobin A1c (HbA1c) equal to or greater than 7.0% but less than 11.0%

• Willing to receive insulin injection while continuing to take the prestudy oral antihyperglycemic medications

• Able to perform self monitoring of blood glucose

Exclusion Criteria:

• Are taking any other glucose-lowering agents other than metformin, sulfonylurea or Thiazolidinedione (Pioglitazone)

• Have taken acarbose, miglitol, pramlintide, exenatide, repaglinide, or nateglinide in the past 6 weeks, or for a total of 30 days or more, in the last 24 weeks

• Have a body mass index greater than 35 kg/m2

• History or presence of kidney disease

• Have cardiac disease (Class III or IV)